Veracyte | VCYT - Cash And Equivalent


Veracyte reported $299.52M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Agenus USD 18.74M 16.26M Jun/2026
Agilent USD 1.76B 49M Jun/2026
Anika Therapeutics USD 38.41M 2.61M Jun/2026
Arrowhead Research USD 19.68M 127.85M Jun/2026
Bruker USD 184.9M 51.5M Jun/2026
Heron Therapeutics USD 20.72M 5.4M Jun/2026
Illumina USD 1.09B 329M Mar/2026
Intrexon USD 9.34M 1.77M Jun/2024
Karyopharm Therapeutics USD 90.85M 30.31M Mar/2026
Laboratory Of America USD 141.8M 839.3M Jun/2026
Ligand Pharmaceuticals USD 1.01B 891.62M Jun/2026
Myriad Genetics USD 115.2M 9.2M Jun/2026
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Siemens EUR 8.66B 6.6B Mar/2026
Sonic Healthcare AUD 645M 25.39M Jun/2024
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026
Veracyte USD 299.52M 36.38M Jun/2026
Waters USD 539M 77M Jun/2026